Last reviewed · How we verify
SORAFENIB TOSYLATE
At a glance
| Generic name | SORAFENIB TOSYLATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2005 |
Approved indications
Common side effects
Key clinical trials
- Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma (PHASE1)
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia (PHASE1)
- Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma (PHASE1)
- Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab (PHASE2)
- Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer (PHASE2)
- Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer (PHASE1, PHASE2)
- Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer (PHASE3)
- Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SORAFENIB TOSYLATE CI brief — competitive landscape report
- SORAFENIB TOSYLATE updates RSS · CI watch RSS